Abbreviations: APRIL = a proliferation-inducing ligand; BAFF = B-cell-activating factor; BAFF-R = B-cell-activating factor receptor; BCMA = B-cell-maturation antigen; CTLA4 = cytotoxic T ...

Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on March 6, 2025, the Compensation Committee granted inducement ...

The two proteins, called BAFF and APRIL, play a key role in the development of autoimmune diseases. The biotech is developing the drug, also dubbed ALPN-303, in renal indications and autoimmune ...

Studies of the consequences of BAFF overexpression have been complemented by studies investigating the effects of blocking either BAFF or both BAFF and APRIL (a proliferation inducing ligand, also ...

Novartis also has an anti-APRIL antibody called zigakibart in phase 3 trials, while Vertex Pharma has a dual antagonist of BAFF and APRIL, povetacicept, which it acquired as part of its takeover ...

next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B cell mediated diseases Completed two equity financings in 2024 ...